Mammalian target of rapamycin inhibitor everolimus is a novel agent used in endocrine
therapy resistant hormone receptor positive metastatic breast cancer. Its use has
been associated with clinically significant improvement in the otherwise dismal outcomes
of this subset of patients. Rash is a common adverse effect associated with everolimus.
However, Hand-foot syndrome is an uncommon toxicity with the use of this drug. We
report a case of Grade 3 hand-foot syndrome following institution of everolimus therapy
and describe its successful management.
Keywords
Breast cancer - everolimus - hand-foot syndrome - mammalian target of rapamycin inhibitors
- palmar-plantar erythrodysesthesia
